Fleming Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Fleming Pharmaceuticals's estimated annual revenue is currently $9.4M per year.
- Fleming Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Fleming Pharmaceuticals has 47 Employees.
- Fleming Pharmaceuticals grew their employee count by -2% last year.
Fleming Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Administrative Assistant | Reveal Email/Phone |
Fleming Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2720.7M | 8460 | 7% | N/A | N/A |
#2 | $13.5M | 67 | 3% | N/A | N/A |
#3 | $9.2M | 46 | -4% | N/A | N/A |
#4 | $19.9M | 99 | 60% | N/A | N/A |
#5 | $48.4M | 241 | 11% | N/A | N/A |
#6 | $1.9M | 19 | 58% | N/A | N/A |
#7 | $6M | 30 | -9% | N/A | N/A |
#8 | $13.1M | 65 | 12% | N/A | N/A |
#9 | $1137.5M | 3537 | 3% | $97M | N/A |
#10 | $18.5M | 92 | -13% | N/A | N/A |
What Is Fleming Pharmaceuticals?
Specializing in the development and manufacture of innovative prescription and over-the-counter (OTC) therapies, privately held Fleming Pharmaceuticals is the proud maker of MAGONATE®, NEPHROCAPS®, NEPHROCAPS® QT, ThyroShield®, ProBarimin QT® and the OCEAN® Nasal Care line of products. Established in 1960, the company has developed products for a variety of clinical conditions in allergy, pediatrics, nephrology, nutrition, and obstetrics/gynecology. Based in the greater St. Louis area, our fully integrated headquarter facility houses state-of-the-art liquid and solid pharmaceutical manufacturing and packaging, analytical microbiological laboratories, research and development, distribution, marketing, and business administration functions.
keywords:N/AN/A
Total Funding
47
Number of Employees
$9.4M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.7M | 47 | 2% | N/A |
#2 | $8.7M | 48 | 2% | N/A |
#3 | $35M | 48 | 109% | N/A |
#4 | $8.9M | 49 | 0% | N/A |
#5 | $6.8M | 49 | 4% | N/A |